Swiss Re AG · SIX:SREN
Swiss Re — Virta Health — Investor Presentation (October 2023)
20 slides from Swiss Re's investor presentation, October 2023
Slide 1: The Leader in Type 2 Diabetes Reversal
The Leader in Type 2 Diabetes Reversal Adam Wolfberg, MD, MPH
Slide 2: Agenda
Agenda Intro Program overview Outcomes
Slide 3: Purpose: Reverse diabetes in 100 million people by 2025
PURPOSE * “i REVERSE DIABETES “IN 100 MILLION PEOPLE BY 2025 NO
Slide 4: Agenda
Agenda Intro Program overview Outcomes
Slide 5: Number of people with diabetes and economic cost in US
$404B Number of people Economic cost with diabetes in US of diabetes in US Cost data from Timothy M. Dall, et. al. The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnos ed Diabetes, Gestational Diabetes Mellitus, and Prediabetes. Diabetes Care 1 September 2019; 42 (9)
Slide 6: How Virta works
How Virta works NUTRITIONAL ADVANCED THERAPY TELEHEALTH Reduces blood sugar and Ensures engagement, safety, dependence on medications + and sustainability Patient ADA Low carb Tailored Intensive Remote Medication cited approach to n=1 coaching monitoring management
Slide 7: Patient experience: clinical care
Patient experience: clinical care Nutritional Health Biomarker Provider-led Changes Coaching Logging Deprescription Patients engage in personalized Patients engage in frequent chats Patients track blood glucose, Providers monitor patient biomarkers to carbohydrate restriction. with dedicated health
Slide 8: Virta has a B2B2C business model with Fortune 500 and government customers
Virta has a B2B2C business model, with several Fortune 500 and large government organizations as customers...
Slide 9: Agenda
Agenda Intro Program overview Outcomes
Slide 10: With peer-reviewed and validated outcomes, Virta is changing the conversation around diabetes
With peer-reviewed and validated outcomes, Virta is changing the conversation around diabetes 5-year clinical trial with 10 peer- Nutritional approach in Outcomes validated by International consensus on reviewed publications to date ADA Standards of Care independent scientists diabetes remission def
Slide 11: Virta has delivered sustained diabetes reversal at scale
Virta has delivered sustained diabetes reversal at scale Diabetes Reversal1 Insulin Reduction2 1. Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612. For patients completing 1 year of treatment. Diabetes reversal defined as patients achieving sub-diabetic A1c without diabetes-specific medication
Slide 12: Virta delivers unmatched outcomes across full spectrum
Virta delivers unmatched outcomes across full spectrum Diabetes Prediabetes Obesity Diabetes Reversal Reversal Reversal Management Virta 54% 1 3% 2 12% 2 15-25% 3 diabetes Progress to T2D weight loss transition to reversal Outcome reversal rate diagnosis over 2 years at 2 years (target) 15% 4 2% 5 B
Slide 13: Virta provides a sustainable path to clinical weight loss
Virta provides a sustainable path to clinical weight loss, for patients who want to avoid costly medications Nutritional Pharmaceutical semaglutide (GLP-1 ra) tirzepatide (GIP/GLP-1 ra) Virta 2.4 mg weekly injection 15 mg weekly injection Setting Real-World 1 RCT 2 RCT 3 Duration of Treatment 72 wee
Slide 14: Meaningful reductions in A1c for patients of all racial and ethnic backgrounds
Virta delivers meaningful reductions in A1c for patients of all racial and ethnic backgrounds Average Lab HbA1c by race and ethnicity at 6 months Virta Health Registry. Covariate-adjusted mean A1c at baseline and 6 months T2D reversal patients retained at least 180 days (83% retention) with race and
Slide 15: Substantial A1c reductions regardless of socioeconomic conditions
Virta delivers substantial reductions in A1c in type 2 diabetes patients regardless of socioeconomic conditions of their local area HbA1c at Enrollment and at 6 Months on Virta by ADI Quintile ADI (Area Deprivation Index) reflects a geographic area’s level of socioeconomic deprivation and is associa
Slide 16: Kevin: Virta patient story
Kevin Pricing Analyst, US Foods VIrta patient for 4+ years Watch Kevin’s Story Results after 6 months on Virta Rx Elimination Insulin, Trulicity, Glipizide Annualized out-of-pocket Cost Savings $6,000 savings alone from diabetes Rx elimination 7.5% to 6.4% A1C 1.1% (below the diabetes threshold) Wei
Slide 17: Virta
{}virta
Slide 18: Virta provides a sustainable path to clinical weight loss at roughly 10% the cost
Virta provides a sustainable path to clinical weight loss for patients who want to avoid costly medications at roughly 10% the cost of newer prescriptions (note: on list price basis, Virta $149/pmpm vs. Rx ~$1,100-1,300/pmpm) NUTRITIONAL PHARMACEUTICAL semaglutide (GLP-1 ra) tirzepatide (GIP/GLP-1)
Slide 19: Virta enrolls patients from diverse backgrounds and improves A1c across all groups
Virta enrolls patients from diverse backgrounds and improves A1c across all racial and ethnic groups % of Virta patients with T2D self-reporting as… Average HbA1c by race and ethnicity at 6 months2 Black or African American, non-Hispanic 13% Hispanic 12% Asian, non-Hispanic 5% American Indian, Alask
Slide 20: Virta enrolls patients from least and most disadvantaged neighborhoods
Virta enrolls patients from the least and most disadvantaged neighborhoods and improves glucose regardless of local socioeconomic conditions % of T2D patients enrolled across ADI quintiles HbA1c at Enrollment and at 6 Months on Virta by ADI Quintile 2 1 = Lowest Deprivation, 5 = Highest Deprivation